Genmab A/S
GMAB30.900USD
-0.070-0.23%
終値 02/06, 16:00（ET）15分遅れの株価
19.02B時価総額
13.07直近12ヶ月PER
詳細情報 Genmab A/S 企業名
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
Genmab A/Sの企業情報
企業コードGMAB
会社名Genmab A/S
上場日Oct 01, 2000
最高経営責任者「CEO」Van De Winkel (Jan G.J)
従業員数2682
証券種類Depository Receipt
決算期末Oct 01
本社所在地Carl Jacobsens Vej 30
都市VALBY
証券取引所NASDAQ OMX - NASDAQ BASIC
国Denmark
郵便番号2500
電話番号4570202728
ウェブサイトhttps://www.genmab.com/
企業コードGMAB
上場日Oct 01, 2000
最高経営責任者「CEO」Van De Winkel (Jan G.J)
Genmab A/Sの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Jan G.J. Van De Winkel, Ph.D.
Dr. Jan G.J. Van De Winkel, Ph.D.
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Non-Independent Director
Non-Independent Director
--
--
Mr. Anthony Pagano
Mr. Anthony Pagano
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Dr. Paolo Paoletti, M.D.
Dr. Paolo Paoletti, M.D.
Independent Director
Independent Director
--
--
Ms. Pernille Lyngvold Erenbjerg
Ms. Pernille Lyngvold Erenbjerg
Independent Deputy Chairman of the Board
Independent Deputy Chairman of the Board
--
--
Ms. Martine J. Van Vugt, Ph.D.
Ms. Martine J. Van Vugt, Ph.D.
Executive Vice President, Chief Strategy Officer
Executive Vice President, Chief Strategy Officer
--
--
Dr. Judith V. Klimovsky, M.D.
Dr. Judith V. Klimovsky, M.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
--
--
Mr. Rolf K. Hoffmann
Mr. Rolf K. Hoffmann
Independent Director
Independent Director
--
--
Ms. Deirdre P. Connelly
Ms. Deirdre P. Connelly
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Jan G.J. Van De Winkel, Ph.D.
Dr. Jan G.J. Van De Winkel, Ph.D.
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Non-Independent Director
Non-Independent Director
--
--
Mr. Anthony Pagano
Mr. Anthony Pagano
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Dr. Paolo Paoletti, M.D.
Dr. Paolo Paoletti, M.D.
Independent Director
Independent Director
--
--
Ms. Pernille Lyngvold Erenbjerg
Ms. Pernille Lyngvold Erenbjerg
Independent Deputy Chairman of the Board
Independent Deputy Chairman of the Board
--
--
Ms. Martine J. Van Vugt, Ph.D.
Ms. Martine J. Van Vugt, Ph.D.
Executive Vice President, Chief Strategy Officer
Executive Vice President, Chief Strategy Officer
--
--
収益内訳
通貨: USD更新時刻: Tue, Jan 6
通貨: USD更新時刻: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
事業別USD
会社名
収益
比率
Royalties
841.00M
82.29%
Net product sales
104.00M
10.18%
Milestone payments
53.00M
5.19%
Collaboration revenue
17.00M
1.66%
Reimbursement income
7.00M
0.68%
会社から関連データがまだ開示されていません。
事業別
地域別
事業別USD
会社名
収益
比率
Royalties
841.00M
82.29%
Net product sales
104.00M
10.18%
Milestone payments
53.00M
5.19%
Collaboration revenue
17.00M
1.66%
Reimbursement income
7.00M
0.68%
株主
更新時刻: Sun, Feb 1
更新時刻: Sun, Feb 1
株主統計
種類
株主統計
株主統計
比率
Orbis Investment Management Ltd.
1.80%
AllianceBernstein L.P.
1.78%
Paradigm BioCapital Advisors LP
0.62%
Arrowstreet Capital, Limited Partnership
0.59%
Harding Loevner LP
0.57%
他の
94.64%
株主統計
株主統計
比率
Orbis Investment Management Ltd.
1.80%
AllianceBernstein L.P.
1.78%
Paradigm BioCapital Advisors LP
0.62%
Arrowstreet Capital, Limited Partnership
0.59%
Harding Loevner LP
0.57%
他の
94.64%
種類
株主統計
比率
Investment Advisor/Hedge Fund
4.95%
Investment Advisor
3.48%
Hedge Fund
1.96%
Research Firm
0.19%
Pension Fund
0.03%
Bank and Trust
0.02%
Family Office
0.02%
Venture Capital
0.01%
他の
89.33%
機関投資家保有株
更新時刻: Thu, Jan 1
更新時刻: Thu, Jan 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
536
65.41M
10.62%
-9.95M
2025Q3
515
64.81M
10.54%
-15.68M
2025Q2
501
65.30M
10.31%
-6.21M
2025Q1
515
65.99M
10.42%
-5.32M
2024Q4
512
61.76M
9.33%
+621.44K
2024Q3
493
53.46M
8.41%
-4.14M
2024Q2
495
49.90M
7.86%
-6.30M
2024Q1
501
49.04M
7.53%
-7.16M
2023Q4
490
47.86M
7.32%
-6.37M
2023Q3
479
48.54M
7.43%
+204.98K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Orbis Investment Management Ltd.
11.08M
1.8%
+3.16M
+39.87%
Sep 30, 2025
AllianceBernstein L.P.
10.95M
1.78%
+291.54K
+2.73%
Sep 30, 2025
Paradigm BioCapital Advisors LP
3.82M
0.62%
+3.82M
--
Sep 30, 2025
Arrowstreet Capital, Limited Partnership
3.64M
0.59%
+188.76K
+5.46%
Sep 30, 2025
Harding Loevner LP
3.48M
0.57%
+561.05K
+19.19%
Sep 30, 2025
Two Sigma Investments, LP
2.82M
0.46%
-615.53K
-17.90%
Sep 30, 2025
Renaissance Technologies LLC
2.82M
0.46%
+54.79K
+1.98%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
2.61M
0.42%
+101.63K
+4.06%
Sep 30, 2025
First Trust Advisors L.P.
1.69M
0.27%
-82.92K
-4.68%
Sep 30, 2025
Parametric Portfolio Associates LLC
1.58M
0.26%
+391.90K
+32.97%
Sep 30, 2025
詳細を見る
関連ETF
更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
Tema Oncology ETF
4.2%
First Trust NYSE Arca Biotechnology Index Fund
3.02%
WisdomTree BioRevolution Fund
1.31%
iShares Biotechnology ETF
1.15%
AB Disruptors ETF
0.69%
JPMorgan Healthcare Leaders ETF
0.28%
First Trust NASDAQ BuyWrite Income ETF
0.26%
ProShares Ultra Nasdaq Biotechnology
0.12%
Invesco Nasdaq Biotechnology ETF
0.12%
ActivePassive International Equity ETF
0.12%
詳細を見る
Tema Oncology ETF
比率4.2%
First Trust NYSE Arca Biotechnology Index Fund
比率3.02%
WisdomTree BioRevolution Fund
比率1.31%
iShares Biotechnology ETF
比率1.15%
AB Disruptors ETF
比率0.69%
JPMorgan Healthcare Leaders ETF
比率0.28%
First Trust NASDAQ BuyWrite Income ETF
比率0.26%
ProShares Ultra Nasdaq Biotechnology
比率0.12%
Invesco Nasdaq Biotechnology ETF
比率0.12%
ActivePassive International Equity ETF
比率0.12%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
配当落ち日
種類
比率
データなし
日付
配当落ち日
種類
比率
データなし
